Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNT005
MIFTS: 56

Central Nervous System Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Central Nervous System Lymphoma

About this section

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 15
Primary Central Nervous System Lymphoma 73
Primary Cns Lymphoma 12
Cns Lymphoma 73
Microglioma 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Blood diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 35 200.5
NCIt 50 C9301
SNOMED-CT 68 21964009 69110006
Sources

Summaries for Central Nervous System Lymphoma

About this section
Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (MYD88, Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are NF-KappaB Family Pathway and Selenium Micronutrient Network. The drugs leucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Central Nervous System Lymphoma

About this section

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 34.2 BCL6 CD274 IL2 MGMT MYD88
2 intraocular lymphoma 32.6 BCL6 IL10
3 acquired immunodeficiency syndrome 30.7 BCL6 IL10 IL2 TP53
4 human immunodeficiency virus infectious disease 30.3 CXCL12 IL10 IL2
5 testicular lymphoma 29.9 BCL6 FOXP1 MYD88
6 leukemia, chronic lymphocytic 29.7 BCL6 CXCL12 IL2 TP53
7 myeloma, multiple 29.4 CDKN2A CXCL12 IL2 PRDM1 TP53
8 diffuse large b-cell lymphoma 29.4 BCL6 FOXP1 MALT1 MYD88 PRDM1 TP53
9 b-cell lymphomas 29.3 BCL6 CDKN2A FOXP1 MALT1 MGMT PRDM1
10 lymphoma, non-hodgkin, familial 29.3 BCL6 CXCL12 IL2 MALT1 TP53
11 lymphoma 11.4
12 aids - neurological complications 11.2
13 glioblastoma 10.5
14 reticulum cell sarcoma 10.5
15 glioma 10.4
16 multiple sclerosis 10.3
17 glioblastoma multiforme 10.3
18 meningitis 10.2
19 encephalitis 10.2
20 primary cutaneous diffuse large b-cell lymphoma, leg type 10.2 CDKN2A MYD88
21 anaplastic oligodendroglioma 10.2 CDKN2A MGMT
22 hepatitis 10.2
23 toxoplasmosis 10.2
24 lymphoepithelioma-like thymic carcinoma 10.2 CD274 CDKN2A
25 histiocytic sarcoma 10.2
26 retinitis pigmentosa 22 10.2 CDKN2A IL10
27 colon lymphoma 10.2 BCL6 CDKN2A
28 gaucher disease, type ii 10.2 IL10 IL2
29 bladder squamous cell carcinoma 10.2 CDKN2A TP53
30 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
31 spitz nevus 10.2 CDKN2A TP53
32 bladder carcinoma in situ 10.2 CDKN2A TP53
33 vulva squamous cell carcinoma 10.2 CDKN2A TP53
34 scrotal carcinoma 10.2 CDKN2A TP53
35 diabetes insipidus 10.2
36 vulvar disease 10.2 CDKN2A TP53
37 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
38 bartholin's gland disease 10.2 CDKN2A TP53
39 breast giant fibroadenoma 10.2 CDKN2A MGMT
40 clonorchiasis 10.2 IL10 IL2
41 anal squamous cell carcinoma 10.1 CDKN2A TP53
42 megaesophagus 10.1 CDKN2A TP53
43 glycogen-rich clear cell breast carcinoma 10.1 CDKN2A TP53
44 gastric adenosquamous carcinoma 10.1 CDKN2A TP53
45 fibrillary astrocytoma 10.1 MGMT TP53
46 anogenital venereal wart 10.1 CDKN2A TP53
47 balanoposthitis 10.1 CDKN2A IL2
48 cervix uteri carcinoma in situ 10.1 CDKN2A TP53
49 paracoccidioidomycosis 10.1 IL10 IL2 MYD88
50 uterus carcinoma in situ 10.1 CDKN2A TP53

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma
Sources

Symptoms & Phenotypes for Central Nervous System Lymphoma

About this section

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.12 CD274
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.12 PRDM1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.12 CD274 MGMT PRDM1 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.12 CD274 PRDM1 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.12 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.12 PRDM1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.12 PRDM1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.12 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.12 PRDM1 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.12 TP53
11 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.12 MGMT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.12 CD274
13 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.12 CD274 PRDM1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.12 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.12 TP53
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.12 MGMT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.12 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.12 MGMT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.12 PRDM1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.12 CD274
21 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.12 MGMT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.12 PRDM1
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CDKN2A IL10 IL2 MALT1 MYD88 TP53
24 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CDKN2A IL10 IL2 MALT1 MYD88 TP53
25 Decreased TP53 mRNA expression GR00389-S-5 9.16 PRDM1 TP53

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
2 cellular MP:0005384 10.16 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
3 homeostasis/metabolism MP:0005376 10.16 BCL6 CD274 CDKN2A IL10 IL2 MGMT
4 mortality/aging MP:0010768 10.15 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
5 cardiovascular system MP:0005385 10.13 BCL6 CDKN2A CXCL12 IL10 IL2 MYD88
6 immune system MP:0005387 10.13 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
7 endocrine/exocrine gland MP:0005379 10.1 BCL6 CDKN2A IL10 IL2 MGMT MYD88
8 liver/biliary system MP:0005370 9.95 BCL6 CDKN2A CXCL12 IL10 IL2 PRDM1
9 no phenotypic analysis MP:0003012 9.85 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
10 muscle MP:0005369 9.8 BCL6 CDKN2A CXCL12 IL10 PRDM1 TP53
11 neoplasm MP:0002006 9.8 CDKN2A IL10 IL2 MGMT MYD88 PRDM1
12 reproductive system MP:0005389 9.56 BCL6 CDKN2A CXCL12 IL10 IL2 MYD88
13 respiratory system MP:0005388 9.17 BCL6 CDKN2A IL10 IL2 MGMT MYD88
Sources

Drugs & Therapeutics for Central Nervous System Lymphoma

About this section

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
2
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
6
Teniposide Approved Phase 4 29767-20-2 34698
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
8
Fotemustine Experimental, Investigational Phase 4
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
28
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
30
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 85622-93-1 5394
31
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
32
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
33
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
34
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
35
Dalteparin Approved Phase 3 9005-49-6
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
38
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
39
Amphotericin B Approved, Investigational Phase 3,Phase 1,Phase 2 1397-89-3 5280965 14956
40
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
43
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 68538-85-2
44
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
45
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
46
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
47
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
48
Carmustine Approved, Investigational Phase 3,Phase 2 154-93-8 2578
49
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
50 Pancreatic Polypeptide Investigational Phase 3 59763-91-6

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
13 BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Recruiting NCT03733327 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
14 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
15 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
16 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Enrolling by invitation NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
17 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
18 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
19 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
20 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL） Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
21 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
22 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
23 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
24 High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Unknown status NCT00801216 Phase 2 High-dose sequential chemotherapy and autologous transplant
25 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
26 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
27 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
28 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
29 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
30 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
31 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
32 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
33 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
34 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
35 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
36 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
37 High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
38 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
39 Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Completed NCT00002940 Phase 2 hydroxyurea
40 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Completed NCT00003061 Phase 2 cytarabine;methotrexate
41 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
42 Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
43 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
44 Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
45 Interferon Alfa in Treating Children With HIV-Related Cancer Completed NCT00002621 Phase 2
46 A Study for Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
47 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
48 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
49 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
50 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)

Search NIH Clinical Center for Central Nervous System Lymphoma

Sources

Genetic Tests for Central Nervous System Lymphoma

About this section
Sources

Anatomical Context for Central Nervous System Lymphoma

About this section

MalaCards organs/tissues related to Central Nervous System Lymphoma:

41
Brain, B Cells, Liver, T Cells, Breast, Kidney, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

19
Central Nervous System
Sources

Publications for Central Nervous System Lymphoma

About this section

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 1029)
# Title Authors Year
1
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. ( 30320386 )
2019
2
Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013). ( 29796994 )
2018
3
Primary central nervous system lymphoma at the cerebellopontine angle mimicking a trigeminal schwannoma: A unique case report and literature review. ( 29656000 )
2018
4
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis. ( 29447417 )
2018
5
Significance of treatment response when managing patients with primary central nervous system lymphoma. ( 29966463 )
2018
6
Apparent diffusion coefficient value for a B-cell central nervous system lymphoma in a cat. ( 29383265 )
2018
7
Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation. ( 29361117 )
2018
8
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
9
Intraventricular treatment of secondary central nervous system lymphoma - Case study and literature overview. ( 29703403 )
2018
10
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2018
11
MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. ( 29258950 )
2018
12
Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. ( 29633883 )
2018
13
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
14
Stereotactic brachytherapy with iodine-125 seeds plus temozolomide induce complete and durable remission in a patient with recurrent primary central nervous system lymphoma. ( 29960094 )
2018
15
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. ( 29331383 )
2018
16
Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. ( 29438500 )
2018
17
B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. ( 29871654 )
2018
18
Spinal primary central nervous system lymphoma: Case report and literature review. ( 29429785 )
2018
19
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents? ( 29804159 )
2018
20
Primary central nervous system lymphoma presenting as growing intracerebral hemorrhage. ( 29803066 )
2018
21
Isolated acute vestibular syndrome due to presumed primary central nervous system lymphoma involving the dorsal medulla. ( 29936666 )
2018
22
Craniotomy and Survival for Primary Central Nervous System Lymphoma. ( 29660011 )
2018
23
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. ( 29741421 )
2018
24
Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. ( 29323247 )
2018
25
Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma. ( 29432597 )
2018
26
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( 29679773 )
2018
27
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
28
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma. ( 29662865 )
2018
29
<sup>18</sup>F-FDG PET/CT in immunocompetent patients with primary central nervous system lymphoma: Differentiation from glioblastoma and correlation with DWI. ( 29857862 )
2018
30
A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. ( 29744624 )
2018
31
A case of primary central nervous system lymphoma arising at the site of remote herpes encephalitis. ( 29382621 )
2018
32
Letter to the Editor Regarding &amp;quot;Natalizumab-Associated Primary Central Nervous System Lymphoma&amp;quot;. ( 29958368 )
2018
33
Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. ( 29891112 )
2018
34
Central nervous system lymphoma mimicking Bell palsy. ( 29883310 )
2018
35
Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible? ( 29559300 )
2018
36
Secondary central nervous system lymphoma: spectrum of morphological MRI appearances. ( 29559780 )
2018
37
Novel biomarker, phosphorylated T-LAK cell-originated protein kinase (p-TOPK) can predict outcome in primary central nervous system lymphoma. ( 29575092 )
2018
38
Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma. ( 29605422 )
2018
39
Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach. ( 29626238 )
2018
40
A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. ( 29633112 )
2018
41
Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma. ( 29877882 )
2018
42
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. ( 29937999 )
2018
43
The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma. ( 29982995 )
2018
44
Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera. ( 29984752 )
2018
45
Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma. ( 29984760 )
2018
46
Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). ( 29986691 )
2018
47
Novel agents for primary central nervous system lymphoma: evidence and perspectives. ( 29986908 )
2018
48
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. ( 29988979 )
2018
49
The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma. ( 29998979 )
2018
50
The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System Lymphoma. ( 30016483 )
2018
Sources

Variations for Central Nervous System Lymphoma

About this section

Cosmic variations for Central Nervous System Lymphoma:

9 (show all 34)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 17:7674221-7674221 5
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 6:137881219-137881219 5
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 4:105261838-105261838 5
4 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 3:177033132-177033132 5
5 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 3:177050103-177050103 5
6 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 3:177033011-177033011 5
7 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 3:177033131-177033131 5
8 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 3:177033052-177033052 5
9 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 3:177053829-177053829 5
10 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 3:177051701-177051701 5
11 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 3:177050062-177050062 5
12 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 3:177033113-177033113 5
13 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 3:177051702-177051702 5
14 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 3:177053907-177053907 5
15 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 3:177033051-177033051 5
16 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 3:177050580-177050580 5
17 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 3:177033126-177033126 5
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 17:42207711-42207711 5
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 17:42322402-42322402 5
20 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 6:106088449-106088449 5
21 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 6:106099553-106099553 5
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 3:38141150-38141150 5
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 12:25245351-25245351 5
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 19:17838299-17838299 5
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 2:25240417-25240417 5
26 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 17:63929439-63929439 5
27 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 17:63929438-63929438 5
28 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 17:63929439-63929439 5
29 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 17:63929439-63929439 5
30 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 17:63929438-63929438 5
31 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 17:63929434-63929434 5
32 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 7:2945834-2945834 5
33 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 7:2945834-2945834 5
34 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 7:2938686-2938686 5

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma
Sources

Expression for Central Nervous System Lymphoma

About this section
Search GEO for disease gene expression data for Central Nervous System Lymphoma.
Sources

Pathways for Central Nervous System Lymphoma

About this section

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
NF-KappaB Family Pathway 64
Show member pathways
 12.46 CXCL12 IL2 MALT1 MYD88
2
Selenium Micronutrient Network 1
Show member pathways
 11.96 IL2 MTR TCN2 TP53
3
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 11.94 CXCL12 IL10 IL2 TP53
4
Direct p53 effectors 1
11.82 BCL6 PRDM1 TP53
5
NF-kappaB Signaling 4
11.74 BCL6 CD274 CXCL12 IL10 IL2 MALT1
6
DNA Damage Response (only ATM dependent) 1
11.73 BCL6 CDKN2A TP53
7
Interleukin-4 and 13 signaling 66
11.71 BCL6 IL10 TP53
8
Glioblastoma Multiforme 64
11.68 CDKN2A MGMT TP53
9
Jak-Stat Signaling Pathway (sino) 67
11.63 CXCL12 IL10 IL2
10
NF-kappa B signaling pathway 37
11.56 CXCL12 MALT1 MYD88
11
C-type lectin receptor signaling pathway 37
Show member pathways
 11.49 IL10 IL2 MALT1 MYD88
12
Regulation of TP53 Expression and Degradation 66
Show member pathways
 11.41 CDKN2A PRDM1 TP53
13
B Cell Development Pathways 65
11.16 BCL6 IL10 PRDM1
14
Photodynamic therapy-induced AP-1 survival signaling. 1
11.04 CDKN2A IL2 TP53
15
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.91 CDKN2A TP53
16
TP53 Network 1
Show member pathways
 10.9 CDKN2A TP53
17
Cobalamin (Cbl, vitamin B12) transport and metabolism 66
10.87 MTR TCN2
Sources

GO Terms for Central Nervous System Lymphoma

About this section

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.87 BCL6 CDKN2A IL10 TP53
2 positive regulation of gene expression GO:0010628 9.86 CDKN2A MYD88 PRDM1 TP53
3 negative regulation of cell growth GO:0030308 9.7 BCL6 CDKN2A TP53
4 negative regulation of cell-matrix adhesion GO:0001953 9.55 BCL6 CDKN2A
5 cytokine-mediated signaling pathway GO:0019221 9.55 BCL6 IL10 IL2 MYD88 TP53
6 cobalamin metabolic process GO:0009235 9.54 MTR TCN2
7 negative regulation of B cell proliferation GO:0030889 9.51 CDKN2A IL10
8 regulation of inflammatory response GO:0050727 9.5 BCL6 FOXP1 MYD88
9 negative regulation of growth of symbiont in host GO:0044130 9.49 IL10 MYD88
10 positive regulation of interleukin-17 production GO:0032740 9.48 IL2 MYD88
11 replicative senescence GO:0090399 9.46 CDKN2A TP53
12 positive regulation of regulatory T cell differentiation GO:0045591 9.43 BCL6 IL2
13 response to molecule of bacterial origin GO:0002237 9.4 IL10 MALT1
14 regulation of tumor necrosis factor production GO:0032680 9.37 FOXP1 MYD88
15 type 2 immune response GO:0042092 9.26 BCL6 IL10
16 negative regulation of apoptotic process GO:0043066 9.17 BCL6 IL10 IL2 MALT1 MGMT MYD88
17 negative regulation of B cell apoptotic process GO:0002903 9.13 BCL6 FOXP1 IL2

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cobalamin binding GO:0031419 9.16 MTR TCN2
2 kinase activator activity GO:0019209 8.96 IL2 MALT1
3 protein self-association GO:0043621 8.92 FOXP1 MALT1 MYD88 TP53
4 protein binding GO:0005515 10.07 BCL6 CD274 CDKN2A CXCL12 FOXP1 IL10
Sources

Sources for Central Nervous System Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....